Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III, Stratified, Randomized, Controlled, Observer-Blind, Multicenter Study to Evaluate the Safety, Tolerability, and Immunogenicity of Two Doses of aH5N1when Administered to Adult and Elderly Subjects With and Without Immunosuppressive Conditions

NCT02107807 is registered in ClinicalTrials.gov with Seqirus as lead sponsor.

NCT NCT02107807
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02107807 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III, Stratified, Randomized, Controlled, Observer-Blind, Multicenter Study to Evaluate the Safety, Tolerability, and Immunogenicity of Two Doses of aH5N1when Administered to Adult and Elderly Subjects With and Without Immunosuppressive Conditions
Lead sponsor
Seqirus
Phase
Phase 3
Overall status
Completed
Start date
April 30, 2014
Completion date
May 31, 2015
Enrollment
539 (actual)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

flu, avian, flu, human, influenza, influenza a virus, h5n1 subtype, influenza, human